https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/accounts-payable https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/accounts-payable-and-accrued-liabilities-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/accretion-amortization-of-discounts-and-premiums-investments https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/accrued-income-taxes-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/accrued-liabilities-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/accumulated-depreciation https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/acquisition-contingent-consideration-arrangements-change-in-amount-of-contingent-consideration-liability https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/activist-13d-13g-form-sc-13d https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/activist-13d-13g-form-sc-13g https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/activist-13d-13g-form-schedule-13g https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/additional-paid-in-capital https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/additional-paid-in-capital-common-stock https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/advertising-expense https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/allocated-share-based-compensation-expense https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/amended-reports-10-k https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/amortization https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/aoci https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/asset-impairment-charges https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/assets-of-disposal-group-including-discontinued-operation-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/available-for-sale-accumulated-gross-unrealized-gain-before-tax https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/available-for-sale-accumulated-gross-unrealized-loss-before-tax https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/available-for-sale-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/available-for-sale-debt-accumulated-gross-unrealized-gain-before-tax https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/available-for-sale-debt-accumulated-gross-unrealized-loss-before-tax https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/available-for-sale-debt-amortized-cost-basis https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/available-for-sale-debt-maturities-amortized-cost https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/available-for-sale-debt-maturities-within-one-year-fair-value https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/available-for-sale-debt-securities https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/available-for-sale-fair-value-disclosure https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/available-for-sale-gross-realized-gain-loss-net https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/available-for-sale-gross-realized-gains https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/available-for-sale-gross-unrealized-gain https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/available-for-sale-gross-unrealized-losses https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/available-for-sale-in-unrealized-loss-positions-qualitative-disclosure-number-of-positions https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/available-for-sale-in-unrealized-loss-positions-qualitative-disclosure-number-of-positions-1 https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/available-for-sale-in-unrealized-loss-positions-qualitative-disclosure-number-of-positions-less-than-one-year https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/available-for-sale-securities https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/available-for-sale-unrealized-loss-position-less-than-12-months-aggregate-losses https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/available-for-sale-unrealized-loss-position-less-than-12-months-aggregate-losses-2 https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/available-for-sale-unrealized-loss-position-less-than-twelve-months-fair-value https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/basic-shares https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/capital-expenditures https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/capital-expenditures-incurred-but-not-yet-paid https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/capital-lease-obligations-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/cash-and-cash-equivalents-change https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/cash-and-equivalents https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/cash-and-restricted-cash https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/cash-cash-equivalents-and-short-term-investments https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/cash-flow-breakdown https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/cash-provided-by-used-in-investing-activities-discontinued-operations https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/cash-provided-by-used-in-operating-activities-discontinued-operations https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/common-stock-capital-shares-reserved-for-future-issuance https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/common-stock-dividends-per-share-cash-paid https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/common-stock-value https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/comprehensive-income https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/contractual-obligation-due-in-next-twelve-months https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/conversion-of-stock-amount-converted https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/convertible-long-term-notes-payable https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/convertible-preferred-stock-shares-reserved-for-future-issuance https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/cost-of-revenue https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/costs-and-expenses https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/cover-page-shares-outstanding https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/current-assets https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/current-federal-state-and-local-tax-expense-benefit https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/current-federal-tax-expense-benefit https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/current-income-tax-expense-benefit https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/current-liabilities https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/current-portion-of-long-term-debt https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/current-state-and-local-tax-expense-benefit https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/debt-conversion-converted-instrument-amount https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/debt-conversion-original-debt-amount https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/debt-face-amount https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/debt-interest-rate-stated-percentage https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/debt-issued https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/debt-maturing-in-year-four https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/debt-maturing-in-year-three https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/debt-maturing-in-year-two https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/debt-repaid https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/debt-securities-held-to-maturity-amortized-cost-after-allowance-for-credit-loss-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/debt-unamortized-discount https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/deconsolidation-gain-or-loss-amount https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/decrease-in-restricted-cash https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/deferred-compensation-arrangement-with-individual-common-stock-reserved-for-future-issuance https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/deferred-credits-and-other-liabilities-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/deferred-credits-and-other-liabilities-noncurrent https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/deferred-finance-costs-current-net https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/deferred-finance-costs-net https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/deferred-rent-credit-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/deferred-rent-credit-noncurrent https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/deferred-revenue https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/deferred-revenue-noncurrent https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/deferred-tax-assets-deferred-income https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/deferred-tax-assets-gross https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/deferred-tax-assets-liabilities-net https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/deferred-tax-assets-net https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/deferred-tax-assets-other https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/deferred-tax-assets-property-plant-and-equipment https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/deferred-tax-assets-stock-compensation https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/deferred-tax-assets-tax-credit-carryforwards https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/deferred-tax-assets-tax-deferred-expense-reserves-and-accruals https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/deferred-tax-liabilities-deferred-expense-deferred-financing-costs https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/deferred-tax-liabilities-goodwill-and-intangible-assets-intangible-assets https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/defined-contribution-plan-employer-discretionary-contribution-amount https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/depreciation https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/depreciation-and-amortization https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/derivative-liabilities-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/diluted-shares https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/discontinued-operation-gain-loss-from-disposal-of-discontinued-operation-before-income-tax https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/discontinued-operation-gain-loss-on-disposal-of-discontinued-operation-net-of-tax https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/discontinued-operation-income-loss-from-discontinued-operation-before-income-tax https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/discontinued-operation-tax-effect-of-discontinued-operation https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/discontinued-operation-tax-effect-of-income-loss-from-disposal-of-discontinued-operation https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/disposal-group-including-discontinued-operation-accrued-income-taxes-payable https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/disposal-group-including-discontinued-operation-assets-noncurrent https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/dividends-common-stock-cash https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/dividends-paid https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/dividends-payable-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/dividends-payable-current-and-noncurrent https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/dividends-preferred-stock-stock https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/effective-tax-rate https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/embedded-derivative-fair-value-of-embedded-derivative-liability https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/employee-related-liabilities-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/eps https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/eps-basic https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/equity-method-investment-realized-gain-loss-on-disposal https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/equity-method-investments https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/fair-value-assets-level-1-to-level-2-transfers-amount https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/financing-cash-flow https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/finite-lived-intangible-assets-accumulated-amortization https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/finite-lived-intangible-assets-amortization-expense-next-twelve-months https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/finite-lived-intangible-assets-amortization-expense-year-five https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/finite-lived-intangible-assets-amortization-expense-year-four https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/finite-lived-intangible-assets-amortization-expense-year-three https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/finite-lived-intangible-assets-amortization-expense-year-two https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/finite-lived-intangible-assets-net https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/form-d-stocks https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/gain-loss-on-disposition-of-assets https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/gain-loss-on-sale-of-equity-investments https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/gain-loss-on-sale-of-property-plant-equipment https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/gains-losses-on-extinguishment-of-debt https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/gains-losses-on-sales-of-assets https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/general-and-administrative-expense https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/goodwill https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/goodwill-impairment-loss https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/held-to-maturity-securities-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/held-to-maturity-securities-fair-value https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/impairment-of-intangible-assets-finitelived https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/impairment-of-intangible-assets-indefinitelived-excluding-goodwill https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/income-loss-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/income-loss-from https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/income-loss-from-discontinued-operations-net-of-tax https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/income-loss-from-discontinued-operations-net-of-tax-attributable-to-reporting-entity https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/income-loss-from-discontinued-operations-net-of-tax-per-basic-and-diluted-share https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/income-loss-from-discontinued-operations-net-of-tax-per-basic-share https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/income-loss-from-discontinued-operations-net-of-tax-per-diluted-share https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/income-loss-from-including-portion-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/income-loss-from-per-basic-and-diluted-share https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/income-loss-from-per-basic-share https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/income-loss-from-per-diluted-share https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/income-tax https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/income-tax-expense-benefit-intraperiod-tax-allocation https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/income-taxes-paid https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/increase-decrease-in-accounts-payable-and-accrued-liabilities https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/increase-decrease-in-accrued-income-taxes-payable https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/increase-decrease-in-accrued-liabilities-and-other-operating-liabilities https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/increase-decrease-in-deferred-revenue https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/increase-decrease-in-inventories https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/increase-decrease-in-other-operating-assets https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/increase-decrease-in-other-operating-capital-net https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/increase-decrease-in-prepaid-deferred-expense-and-other-assets https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/increase-decrease-in-receivables https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/increase-decrease-in-restricted-cash https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/increase-in-restricted-cash https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/indefinite-lived-intangible-assets-excluding-goodwill https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/insider-transactions-preferred https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/insider-transactions-stock-options https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/insider-transactions-warrants https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/intangible-assets-net-excluding-goodwill https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/intangible-assets-net-including-goodwill https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/interest-costs-capitalized https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/interest-expense https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/interest-paid https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/interest-paid-net https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/interest-payable-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/inventory https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/inventory-finished-goods https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/inventory-raw-materials https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/inventory-work-in-process https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/investing-cash-flow https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/investment-income-interest https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/issuance-of-stock-and-warrants-for-services-or-claims https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/liabilities-of-disposal-group-including-discontinued-operation-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/liabilities-of-disposal-group-including-discontinued-operation-noncurrent https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/license-and-services-revenue https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/loans-payable-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/long-term-debt https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/long-term-loans-payable https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/long-term-notes-payable https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/marketable-securities https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/marketable-securities-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/maturities-of-shortterm-investments https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/minority-interest https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/net-cash-from https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/net-cash-from-financing-activities https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/net-cash-from-investing-activities https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/net-cash-from-operating-activities https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/net-change-in-cash https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/net-income https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/net-income-loss-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/net-income-loss-available-to-common-stockholders-basic https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/net-income-loss-available-to-common-stockholders-diluted https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/noncash-or-part-noncash-divestiture-amount-of-consideration-received https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/noncontrolling-interest-decrease-from-deconsolidation https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/nonredeemable-noncontrolling-interest https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/notes-payable https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/notes-payable-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/number-of-operating-segments https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/oci-available-for-sale-adjustment-net-of-tax https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/oci-net-of-tax https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/oci-net-of-tax-2 https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/operating-cash-flow https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/operating-expenses https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/operating-income https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/operating-lease-assets https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/operating-lease-liability https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/operating-lease-payments-due https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/operating-lease-payments-due-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/operating-lease-payments-due-in-five-years https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/operating-lease-payments-due-in-four-years https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/operating-lease-payments-due-in-three-years https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/operating-lease-payments-due-in-two-years https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/operating-leases-rent-expense-net https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/other-accrued-liabilities-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/other-current-liabilities https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/other-income https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/other-noncash-income-expense https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/other-noncurrent-assets https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/other-noncurrent-liabilities https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/other-nonoperating-income-expense https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/other-preferred-stock-dividends-and-adjustments https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/other-sales-revenue-net https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/other-than-temporary-impairment-losses-investments-available-for-sale-securities https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/paid-in-capital-convertible-debt-with-conversion-feature https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/paid-in-capital-dividends-in-excess-of-retained-earnings https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/paid-in-capital-reallocation-of-minority-interest https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/paid-in-capital-stock-compensation https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/paid-in-kind-interest https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/patents-rejected https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/payments-for-proceeds-from-other-investing-activities https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/payments-for-restructuring https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/payments-of-debt-extinguishment-costs https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/payments-of-dividends-preferred-stock-and-preference-stock https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/payments-of-stock-issuance-costs https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/payments-to-acquire-available-for-sale-securities https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/payments-to-acquire-investments https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/payments-to-acquire-marketable-securities https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/preferred-shares-facts https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/preferred-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/preferred-stock-shares-authorized https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/preferred-stock-shares-issued https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/preferred-stock-shares-outstanding https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/prepaid-expense-and-other-assets-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/pretax-income https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/proceeds-from-convertible-debt https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/proceeds-from-debt-net-of-issuance-costs https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/proceeds-from-divestiture-of-businesses-net-of-cash-divested https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/proceeds-from-issuance-initial-public-offering https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/proceeds-from-issuance-of-convertible-preferred-stock https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/proceeds-from-issuance-of-preferred-stock-and-preference-stock https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/proceeds-from-notes-payable https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/proceeds-from-payments-for-other-financing-activities https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/proceeds-from-sale-and-maturity-of-available-for-sale-securities https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/proceeds-from-sale-and-maturity-of-marketable-securities https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/proceeds-from-sale-of-equity-method-investments https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/proceeds-from-sale-of-property-plant-and-equipment https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/proceeds-from-sales-of-business-affiliate-and-productive-assets https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/proceeds-from-stock-issued https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/proceeds-from-stock-options-exercised https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/proceeds-from-warrant-exercises https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/profit-loss https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/property-plant-and-equipment-disposals https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/property-plant-and-equipment-gross https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/property-plant-equipment https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/public-float https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/receivables-net-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/repayments-of-long-term-capital-lease-obligations https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/repayments-of-other-debt https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/repayments-of-senior-debt https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/research-and-development https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/restricted-cash-and-cash-equivalents https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/restricted-cash-and-cash-equivalents-at-carrying-value https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/restricted-cash-and-cash-equivalents-noncurrent https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/restricted-cash-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/restricted-cash-noncurrent https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/restructuring-and-related-cost-number-of-positions-eliminated-period-percent https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/restructuring-charges https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/restructuring-reserve-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/restructuring-reserve-settled-without-cash https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/retained-earnings https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/revenue https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sales-revenue-goods-net https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sec-comment-letters-corresp https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sec-comment-letters-upload https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sec-filings-10-k https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sec-filings-10-q https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sec-filings-15-12g https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sec-filings-25 https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sec-filings-425 https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sec-filings-8-a12b https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sec-filings-8-a12g https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sec-filings-8-k https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sec-filings-ars https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sec-filings-certnas https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sec-filings-ct-order https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sec-filings-def-14a https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sec-filings-defa14a https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sec-filings-defm14a https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sec-filings-defr14a https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sec-filings-dfan14a https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sec-filings-pre-14a https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sec-filings-prec14a https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sec-filings-prem14a https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sec-filings-prer14a https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sec-filings-prrn14a https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sec-filings-regdex https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/secondary-offerings-form-305b2 https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/secondary-offerings-form-424b4 https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/secondary-offerings-form-424b5 https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/secondary-offerings-form-effect https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/secondary-offerings-form-fwp https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/secondary-offerings-form-pos-am https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/secondary-offerings-form-s-1 https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/secondary-offerings-form-s-3 https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/secondary-offerings-form-s-3asr https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/secondary-offerings-form-s-8 https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/sga-expense https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/share-based-goods-and-nonemployee-services-transaction-expense https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/share-price https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/shareholders-equity https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/shares-authorized https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/shares-issued https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/shares-issued-shares-new-issues https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/short-term-investments https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-award-accelerated-compensation-cost https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-award-fair-value-assumptions-expected-dividend-rate https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-award-fair-value-assumptions-expected-volatility-rate https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-award-fair-value-assumptions-risk-free-interest-rate https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-award-options-exercises-in-period-average-exercise-price https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-award-options-forfeitures-in-period-average-exercise-price https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-award-options-grants-in-period-average-exercise-price https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-award-plan-modification-incremental-compensation-cost https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-based-compensation https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-compensation-allocation-of-recognized-period-costs-capitalized-amount https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-compensation-unrecognized-cost-stock-options https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-issued-new-shares-sold https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-issued-shares-issued-for-options-exercised https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-issued-shares-issued-shares-conversion-of-convertible-securities https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-issued-shares-issued-value-conversion-of-convertible-securities https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-issued-shares-issued-value-stock-options-exercised https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-options-exercisable-average-exercise-price https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-options-exercisable-intrinsic-value https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-options-exercisable-number https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-options-exercises-in-period-total-intrinsic-value https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-options-forfeitures-in-period https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-options-grants-in-period-grant-date-fair-value https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-options-grants-in-period-gross https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-options-outstanding-average-exercise-price https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-options-outstanding-intrinsic-value https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-options-outstanding-number https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-options-vested-and-expected-to-vest-outstanding-aggregate-intrinsic-value https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-options-vested-and-expected-to-vest-outstanding-average-exercise-price https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-options-vested-and-expected-to-vest-outstanding-number https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stock-split-ratio https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/stockholders-equity-including-portion-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/tax-rate-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/tax-rate-reconciliation-change-in-enacted-tax-rate https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/tax-rate-reconciliation-foreign-income-tax-rate-differential https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/tax-rate-reconciliation-nondeductible-expense https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/tax-rate-reconciliation-nondeductible-expense-share-based-compensation-cost https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/tax-rate-reconciliation-other-adjustments https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/tax-rate-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/tax-rate-reconciliation-tax-credits https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/taxes-payable-current https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/temporary-equity-carrying-amount https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/temporary-equity-carrying-amount-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/temporary-equity-carrying-amount-attributable-to-parent https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/temporary-equity-net-income https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/temporary-equity-shares-issued https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/total-assets https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/total-liabilities https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/total-liabilities-and-equity https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/total-long-term-debt https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/valuation-allowance-amount https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/valuation-allowance-deferred-tax-asset-change-in-amount https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/valuation-allowances-and-reserves-balance https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/valuation-allowances-and-reserves-charged-to-cost-and-expense https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/valuation-allowances-and-reserves-deductions https://stock.noler.com/us/stock/merrimack-pharmaceuticals-inc/weighted-average-number-of-share-outstanding-basic-and-diluted